Bifidobacterium Triple Viable Granules Combined with Montmorillonite Powder in the Therapy of Children with Diarrhea

This study was designed to evaluate the effect of Bifidobacterium triple viable granules combined with montmorillonite powder in children with diarrhea. To this end, 60 children with diarrhea were divided into two groups of equal size, with one receiving montmorillonite powder alone (control) and the other receiving montmorillonite powder plus Bifidobacterium triple viable granules (treatment). The children in the treatment group experienced significantly higher overall relief from diarrhea that was associated with shorter durations of fever, diarrhea, abdominal pain, and vomiting, as well as shorter recovery times for stool characters and stool frequency. Also, the serum levels of C-reactive protein, Interleukin-4, and Interleukin-6 were lower, while Immunoglobulin A, Immunoglobulin G, and Immunoglobulin M levels were higher in the treatment group than the control group (P < 0.05). There were far fewer adverse reactions in the treatment group than in the control group. In summary, Bifidobacterium triple viable granules combined with montmorillonite powder are clinically superior in treating children with diarrhea.